Mereo BioPharma Group (Mereo BioPharma Group) Accounts Payable : $2.35 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Mereo BioPharma Group Accounts Payable?

Mereo BioPharma Group's Accounts Payable for the quarter that ended in Dec. 2023 was $2.35 Mil.

Mereo BioPharma Group's quarterly Accounts Payable declined from Dec. 2022 ($3.49 Mil) to Jun. 2023 ($2.41 Mil) and declined from Jun. 2023 ($2.41 Mil) to Dec. 2023 ($2.35 Mil).

Mereo BioPharma Group's annual Accounts Payable increased from Dec. 2021 ($3.08 Mil) to Dec. 2022 ($3.49 Mil) but then declined from Dec. 2022 ($3.49 Mil) to Dec. 2023 ($2.35 Mil).

Mereo BioPharma Group Accounts Payable Historical Data

The historical data trend for Mereo BioPharma Group's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Accounts Payable Chart

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

8.06

4.31

3.08

3.49

2.35

Mereo BioPharma Group Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable	Get a 7-Day Free Trial												3.08	3.42	3.49	2.41	2.35

Mereo BioPharma Group Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Mereo BioPharma Group Accounts Payable Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group (Mereo BioPharma Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

MAH0:Germany MAH0:Germany

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.